Leinco Technologies Inc. completes acquisition of QED Biosciences to expand antibody capabilities
Acquiring Company
Leinco Technologies
Acquired Company
QED Biosciences
FentonManufacturingBiotechnologyHealth CareDescription
Leinco Technologies has acquired QED Biosciences, a leading provider of antibodies, kits, and recombinant proteins and antigens. This strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics, targeting the IVD and research sectors.
Quick answer
Leinco Technologies is acquiring QED Biosciences, announced September 3, 2024. Leinco Technologies is based in Fenton, Missouri, United States.
- How much did Leinco Technologies pay for QED Biosciences?
- The deal value was not disclosed.
- What does Leinco Technologies do?
- Established in 1992, Leinco Technologies is a specialty manufacturer of early discovery research products, including antibodies, recombinant proteins, ELISA kits, and other life sciences products.
- Where are Leinco Technologies and QED Biosciences based?
- Leinco Technologies is based in Fenton, Missouri, United States.
- Who are the decision-makers at Leinco Technologies?
- Fundz holds 2 contacts at Leinco Technologies. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Manufacturing and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- Merck completes acquisition of investigational B-Cell depletion therapy, CN201, from Curon Biopharmaceutical (October 1, 2024)
- Vitalograph acquires Morgan Scientific to strengthen US commercial footprint (September 23, 2024)
- Veridian Healthcare completes acquisition of Zewa, Inc. to expand its RPM and telehealth segments (September 4, 2024)
- BD completes acquisition of Edwards Lifesciences' Critical Care product group to expand its smart connected care solutions portfolio (September 3, 2024)
- Ultradent Products, Inc. acquires majority stake in i-dental (August 23, 2024)
Who to call at Leinco Technologies, and when
When Leinco Technologies changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Leinco Technologies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Leinco Technologies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Leinco Technologies. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Leinco Technologies makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired QED Biosciences?
QED Biosciences was acquired by Leinco Technologies, based in Fenton. The deal was reported on September 3, 2024. Established in 1992, Leinco Technologies is a specialty manufacturer of early discovery research products, including antibodies, recombinant proteins, ELISA kits, and other life sciences products. Leinco Technologies is privately held and operates in Manufacturing.
When did Leinco Technologies acquire QED Biosciences?
Leinco Technologies's acquisition of QED Biosciences was reported on September 3, 2024. Leinco Technologies has acquired QED Biosciences, a leading provider of antibodies, kits, and recombinant proteins and antigens. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does QED Biosciences do?
QED Biosciences, a Genovis-owned company, is a leading provider of antibodies, kits, and recombinant proteins and antigens catering to the diverse needs of the IVD and research communities. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.